 Biomea Fusion Inc. rallied out of the gate Friday, as shares of the California-based biopharmaceutical company focused on treatment of genetically defined cancers opened 17.6 above the initial public offering price. The company said late Thursday its IPO, which was upsized to 9.0 million shares from 7.5 million shares, priced at 17 a share, at the top of the expected range, as it raised 153 million and was valued at 463.6 million. 